DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Blanke CD, Rankin C, Demetri GD. et al.
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
J Clin Oncol 2008; 26: 626-632
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.